US$3.9bn

Capital Deployed

40+ years

Investing Experience

Active Value Creation

In partnership with our management teams, we combine operational change with introducing artificial intelligence and automation to drive value in each of our investments

Stanley Capital’s involvement in Noden Pharma has reinvigorated our business through unparalleled rigour in the development of our value creation plans, the value-add board of directors they have built around the business and have helped develop an origination approach to our platform M&A strategy not seen in any other investment firm
Alan Markey, CEO – Noden Pharma

Stanley Capital shares our vision to bring innovative technology solutions together with our high calibre medical and scientific resources as we strengthen our end-to-end client offering. Stanley brings technology expertise, deep sector understanding and M&A capability that will help us accelerate our future growth Humaira Qureshi, CEO of Bioclinica Drug Safety and Pharmacovigilance Services Solutions (“DSS”)